[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-339803-105":59,"doc-detail-339803-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","enhancing-urological-cancer-treatment-leveraging-vasodilator-synergistic-potential-with-5-fu-for-improved-therapeutic-outcomes","Enhancing Urological Cancer Treatment - Leveraging Vasodilator Synergistic Potential with 5-FU for Improved Therapeutic Outcomes","","This study investigates vasodilator drugs as additive therapy for urological cancers, focusing on combinations with 5-fluorouracil (5-FU). Cytotoxicity and functional effects were assessed in urological cancer cell lines using MTT, colony formation, and wound healing assays to measure viability, proliferation, and migration. Levosimendan showed moderate anticancer activity, while sildenafil and tezosentan had limited effects. The levosimendan-5-FU combination produced additive cytotoxic interaction, increasing cancer cell killing while sparing normal cells, with effects potentially linked to cAMP modulation and nitric oxide production. The results support using levosimendan alongside 5-FU to lower the 5-FU dose, aiming to reduce side effects without compromising efficacy.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/enhancing-urological-cancer-treatment-leveraging-vasodilator-synergistic-potential-with-5-fu-for-improved-therapeutic-outcomes/339803/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/enhancing-urological-cancer-treatment-leveraging-vasodilator-synergistic-potential-with-5-fu-for-improved-therapeutic-outcomes/339803.png","ImageObject",300,407,{"name":92,"@type":93},"Oliver","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",14,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Which vasodilator drugs were tested with 5-FU in urological cancer cell lines?","Question",{"text":113,"@type":114},"The study evaluated sildenafil, tezosentan, and levosimendan alone and in combination with 5-FU for effects on urological cancer cell lines.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What assays were used to evaluate therapeutic effects in the study?",{"text":118,"@type":114},"Cytotoxic effects and functional outcomes were measured using MTT assays, colony formation assays, and wound healing assays to assess viability, proliferative capacity, and migratory behavior.",{"name":120,"@type":111,"acceptedAnswer":121},"How did the combination of levosimendan with 5-FU affect cancer cells compared with normal cells?",{"text":122,"@type":114},"Levosimendan combined with 5-FU showed an additive interaction that enhanced cytotoxicity against cancer cells while sparing normal cells.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},339803,1790708875,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},8796095461610,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Journal of  \nClinical Medicine  \nArticle  \nEnhancing Urological Cancer Treatment: Leveraging Vasodilator Synergistic Potential with 5-FU for Improved Therapeutic Outcomes  \nEduarda Ribeiro 1,2,3, Barbara Costa 1,2, Lara Marques 1,2, Francisco Vasques-Nóvoa 4 and Nuno Vale 1,2,5, *  \nCitation: Ribeiro, E.; Costa, B.; Marques, L.; Vasques-Nóvoa, F.; Vale, N. Enhancing Urological Cancer Treatment: Leveraging Vasodilator Synergistic Potential with 5-FU for Improved Therapeutic Outcomes. J. Clin. Med. 2024, 13, 4113. [https://](https://)[ ](https://)[doi.org/10.3390/jcm13144113](doi.org/10.3390/jcm13144113)  \nAcademic Editor: Enrico Checcucci  \nReceived: 21 June 2024  \nRevised: 8 July 2024  \nAccepted: 12 July 2024  \nPublished: 14 July 2024  \nCorrection Statement: This article has been republished with a minor change. The change does not affect the scientific content of the article and further details are available within the backmatter of the website version of this article.  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 PerMed Research Group, Center for Health Technology and Services Research (CINTESIS), Rua Doutor Plácido da Costa, 4200-450 Porto, Portugal; [eduardaprr@gmail.com](eduardaprr@gmail.com) (E.R.); [b.c.211297@gmail.com](b.c.211297@gmail.com) (B.C.); [lara.marques2010@hotmail.com](lara.marques2010@hotmail.com) (L.M.)  \n2 CINTESIS@RISE, Faculty of Medicine, University of Porto, Alameda Professor Hernâni Monteiro, 4200-319 Porto, Portugal  \n3 ICBAS—School of Medicine and Biomedical Sciences, University of Porto, Rua Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal  \n4 Department of Surgery and Physiology, Faculty of Medicine, University of Porto, Rua Doutor Plácido da Costa, 4200-450 Porto, Portugal; [fvasquesnovoa@med.up.pt](fvasquesnovoa@med.up.pt)  \n5 Department of Community Medicine, Information and Health Decision Sciences (MEDCIDS), Faculty of Medicine, University of Porto, Rua Doutor Plácido da Costa, 4200-450 Porto, Portugal  \n* [Correspondence: nunovale@med.up.pt](Correspondence: nunovale@med.up.pt); Tel.: +351-220-426-537  \nAbstract: Backgroud: This study investigates the potential of vasodilator drugs as additive therapy in the treatment of urological cancers, particularly in combination with the antineoplastic agent 5-fluorouracil (5-FU) . Methods: The study evaluated the cytotoxic effects of sildenafil, tezosentan and levosimendan alone and in combination with 5-FU on urological cancer cell lines. The assessment included MTT assays, colony formation assays and wound healing assays to determine cell viability, proliferative capacity, and migratory behavior, respectively. Results: Sildenafil and tezosentan showed limited cytotoxic effects, while levosimendan demonstrated moderate anticancer activity. The combination of levosimendan and 5-FU exhibited an additive interaction, enhancing cytotoxicity against cancer cells while sparing normal cells. Levosimendan also inhibited cell migration and proliferation, potentially through mechanisms involving the modulation of cAMP levels and nitric oxide production. Conclusions: The findings suggest that levosimendan can be used in conjunction with 5-FU to reduce the required dose of 5-FU, thereby minimizing side effects without compromising therapeutic efficacy. This study offers a new perspective for enhancing therapeutic outcomes inpatients with urological cancers.  \nKeywords: bladder cancer; combination therapy; drug repurposing; in vitro; prostate cancer  \n1. Introduction  \nCancer continues to be a pressing global health concern, impacting millions of lives worldwide. In 2022, the burden of cancer will remain substantial, with increasing incidence rat","cbCaiui0gg2DOMdf","https://ap.wps.com/l/cbCaiui0gg2DOMdf","pdf",7201499,26,"English","# Abstract\n# Introduction\n# Methods\n# Results\n# Conclusions","[{\"question\":\"Which vasodilator drugs were tested with 5-FU in urological cancer cell lines?\",\"answer\":\"The study evaluated sildenafil, tezosentan, and levosimendan alone and in combination with 5-FU for effects on urological cancer cell lines.\"},{\"question\":\"What assays were used to evaluate therapeutic effects in the study?\",\"answer\":\"Cytotoxic effects and functional outcomes were measured using MTT assays, colony formation assays, and wound healing assays to assess viability, proliferative capacity, and migratory behavior.\"},{\"question\":\"How did the combination of levosimendan with 5-FU affect cancer cells compared with normal cells?\",\"answer\":\"Levosimendan combined with 5-FU showed an additive interaction that enhanced cytotoxicity against cancer cells while sparing normal cells.\"}]","Enhancing Urological Cancer Treatment - Leveraging Vasodilator Synergistic Potential with 5-FU for Improved Therapeutic Outcomes | PDF",1790032319,66,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2bb543342f65bddb69e76a418d704c7c.webp",983,1390,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bba88f8f150e52c7fae54d04671e0bdc.webp",982,1388,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/700d0a4f4e1b06e04342eb760a63684d.webp",981,1387,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e635ae8fbd08b62b5b439c0b3dc003f7.webp",980,1385]